Cargando…

ML-11 Tirabrutinib treatment for recurrent or refractory PCNSL

Since 2020, tirabrutinib which is a Bruton’s tyrosine kinase (BTK) inhibitor has been available for recurrent or refractory PCNSL cases. The number of studies reporting efficiency and adverse effect of tirabrutinib treatment for recurrent or refractory PCNSL has been limited yet. In this study, we i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohka, Fumiharu, Yamaguchi, Junya, Motomura, Kazuya, Aoki, Kosuke, Nishikawa, Tomohide, Kibe, Yuji, Yamazaki, Shintaro, Natsume, Atsushi, Saito, Ryuta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648252/ http://dx.doi.org/10.1093/noajnl/vdab159.090

Ejemplares similares

ML-9 TREATMENT OUTCOMES OF TIRABRUTINIB FOR RELAPSED AND REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN A SINGLE INSTITUTE
por: Ohka, Fumiharu, et al.
Publicado: (2022)

MPC-5 Characteristics of H3 G34-mutant gliomas
por: Kibe, Yuji, et al.
Publicado: (2021)

STMO-6 Impact of the extent of resection on the survival of patients with lower grade gliomas using awake brain mapping
por: Motomura, Kazuya, et al.
Publicado: (2021)

ML-17 Clinical usefulness of Tirabrutinib in recurrent PCNSL: single institute experience
por: Matsuura, Jin, et al.
Publicado: (2021)

Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series
por: Kibe, Yuji, et al.
Publicado: (2023)

MPC-20 CLINICAL AND MOLECULAR FEATURES OF GLIOBLASTOMAS ARISING IN THE SETTING OF LI FRAUMENI SYNDROME
por: Kibe, Yuji, et al.
Publicado: (2022)

ML-12 Clinical impact and management of skin-related disorders during treatment of relapsed PCNSL by tirabrutinib
por: Sasaki, Nobuyoshi, et al.
Publicado: (2021)

NQPC-02 Long-term survival in patients with primary intracranial germ cell tumors treated with surgery, platinum-based chemotherapy, and radiotherapy: a single-institution study
por: Motomura, Kazuya, et al.
Publicado: (2020)

TB-03 Newly Established Meningioma Organoid Model Elucidated an Important Role of FOXM1 in Meningioma Progression
por: Yamazaki, Shintaro, et al.
Publicado: (2020)

Survival Benefit of Supratotal Resection in a Long-term Survivor of IDH-wildtype Glioblastoma: A Case Report and Literature Review
por: YAMAGUCHI, Junya, et al.
Publicado: (2021)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

Rapid detection of the MYD88 L265P mutation for pre‐ and intra‐operative diagnosis of primary central nervous system lymphoma
por: Yamaguchi, Junya, et al.
Publicado: (2023)

Multiple metastases to the bone and bone marrow from a 1p/19q-codeleted and IDH2-mutant anaplastic oligodendroglioma: a case report and literature review
por: Shimizu, Hiroyuki, et al.
Publicado: (2020)

ML-10 Tirabrutinib, a second-generation BTK inhibitor in relapsed and refractory primary CNS lymphoma: A single institute study
por: Mishima, Kazuhiko, et al.
Publicado: (2021)

Supratotal Resection of Gliomas With Awake Brain Mapping: Maximal Tumor Resection Preserving Motor, Language, and Neurocognitive Functions
por: Motomura, Kazuya, et al.
Publicado: (2022)

TB-2 Patient-derived meningioma organoid model demonstrates FOXM1 dependent tumor proliferation
por: Yamazaki, Shintaro, et al.
Publicado: (2021)

ML-14 Re-challenge and maintenance therapy of methotrexate for elderly PCNSL patients with low scored KPS
por: Yamaguchi, Takashi, et al.
Publicado: (2020)

ML-05 One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
por: Mishima, Kazuhiko, et al.
Publicado: (2020)

ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
por: Shinojima, Naoki, et al.
Publicado: (2020)

ML-13 The primary treatment outcomes and future problems of PCNSL elderly patients in our institute
por: Kambe, Atsushi, et al.
Publicado: (2020)

Direct intracranial invasion of eccrine spiradenocarcinoma of the scalp: a case report and literature review
por: Kibe, Yuji, et al.
Publicado: (2022)

ML-16 First clinical experience of administration of Tirabrutinib for the patients with newly diagnosed primary central nervous system lymphoma
por: Onodera, Sho, et al.
Publicado: (2021)

ML-07 High expression of PD-L1 on tumor-associated macrophage is a predictive factor for favorable prognosis in PCNSL
por: Furuse, Motomasa, et al.
Publicado: (2020)

Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
por: Adilijiang, Alimu, et al.
Publicado: (2019)

ML-09 The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group
por: Asano, Kenichiro, et al.
Publicado: (2020)

ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas
por: Aoki, Kosuke, et al.
Publicado: (2021)

ML-5 THE TRANSITION OF THE TREATMENT OF 60 PCNSL CASES AT OUR INSTITUTION AND CLINICAL CONSIDERATIONS
por: Yoshitake, Hidenobu, et al.
Publicado: (2022)

ML-4 POLICY CHANGE TO PCNSL TREATMENT LED BY HEMATOLOGY, AND INITIAL TREATMENT RESULTS
por: Hashiba, Tetsuo, et al.
Publicado: (2022)

H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant
por: Maeda, Sachi, et al.
Publicado: (2020)

Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving tocilizumab: illustrative case
por: Ohno, Masasuke, et al.
Publicado: (2022)

ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020)

CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma
por: Yamaguchi, Junya, et al.
Publicado: (2022)

Current Trends in Targeted Therapies for Glioblastoma Multiforme
por: Ohka, Fumiharu, et al.
Publicado: (2012)

Neurod4 converts endogenous neural stem cells to neurons with synaptic formation after spinal cord injury
por: Fukuoka, Toshiki, et al.
Publicado: (2021)

All-in-One Nanowire Assay System for Capture and Analysis of Extracellular Vesicles from an ex Vivo Brain Tumor Model
por: Chattrairat, Kunanon, et al.
Publicado: (2023)

Recent Molecular and Genetic Findings in Intramedullary Spinal Cord Tumors
por: Nagashima, Yoshitaka, et al.
Publicado: (2022)

Dural Arteriovenous Fistula Mimicking a Brain Tumor on Methionine-positron Emission Tomography: A Case Report
por: HANYU, Taketo, et al.
Publicado: (2022)

ML-18 High-dose chemotherapy supported by autologous stem cell transplant in relapsed and refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2021)

Assessment of Tumor Cells in a Mouse Model of Diffuse Infiltrative Glioma by Raman Spectroscopy
por: Tanahashi, Kuniaki, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2kgpgct61e4mj8t49ekb6s3qvb